These results clearly propose that pre-treatment MGR could be a novel and concise measure of tumor growth kinetics that independently predicts clinical outcome when compared to IMDC risk classification, baseline NLR, baseline CRP and number of prior treatments. This evidence concerns the gene CRP and neoplasm.